Experiences with

Ritonavir

[/i] [i]Several COVID-19 treatments -- nirmatrelvir/ritonavir (Paxlovid), remdesivir (Veklury), and molnupiravir (Lagevrio) -- are expected to work against currently circulating variants, and are approved or authorized to treat patients with mild-to-moderate COVID-19 who are at high risk for progression

In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection." [That sort of has been the suspicion since the very beginning.]

Full access link to the paper: [i]SARS-CoV-2 Virologic Rebound With Nirmatrelvir– Therapy - An Observational Study, Annals of Internal Medicine, Original Research, 14 November 2023.

https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/ Hi All - Inresponse to my two responses I found this from NIH which states that Prednisone and other drugs are safe with Paxlovid

src=rss ) : [i]Consider the oral antivirals nirmatrelvir-ritonavir (Paxlovid) or molnupiravir (Lagevrio) for symptomatic outpatients with confirmed mild to moderate COVID-19 who are within 5 days of the onset of symptoms and at high risk for progressing to severe disease and potential hospitalization

query=TOC&cid=NEJM%20eToc,%20August%2025,%202022%20DM1379474_NEJM_Non_Subscriber&bid=1131122421 looked at "Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge" in Israel, while elsewhere Nirmatrelivir is authorised to be given with Ritonavir, the two oral antivirals being co-packaged

This could be either sotrovimab or nirmatrelvir with ritonavir (Paxlovid), and those who are unable to receive these treatments will be offered remdesivir (Veklury) and then molnupiravir.

Antiviral medications Paxlovid™ (nirmatrelvir/ritonavir), Legevrio™ (molnupiravir), and Veklury® (remdesivir) remain active against currently circulating COVID virus subvariants.

I registered my condition with all the relevant departments and awaited a phone call from a doctor to assess my condition with the view to being offered one of the new treatments, (Nirmatrelvir, Ritonavir, Remdesivir, or Molnupiravir) because I am clinically extremely vulnerable.

Antiviral medications Paxlovid™ (nirmatrelvir/ritonavir), Legevrio™ (molnupiravir), and Veklury® (remdesivir) remain active against currently circulating COVID virus subvariants.

2.Nirmatrelvir and (Paxlovid) has been added as a first-line COVID-19 treatment In many cases, Paxlovid will be offered instead of the antibody infusion, sotrovimab. Paxlovid is an oral treatment meaning that it can be taken without having to attend a hospital.

This is from the FDA fact sheet- PAXLOVID is contraindicated with drugs that are potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance.

responses=147645398 [u]Drug-Drug Interactions Between -Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications:[/u] https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug-drug-interactions/ [u]Management

Careful monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with ritonavir.

Thousands of vulnerable patients could be taking ground-breaking COVID-19 antivirals this winter after the government announced deals to secure 2 new treatments. These treatments should speed up recovery time for COVID-19 patients and the most vulnerable will be eligible first, including the elderly

Initially, 30 mg of ModraDoc006 combined with 200 mg of ritonavir in the morning and 20 mg of ModraDoc006 with 100 mg of ritonavir in the evening were administered on days 1, 8, and 15 of the 21-day cycle.

A triple-antiviral therapy regimen of interferon-beta1, lopinavir/ritonavir, and ribavirin shortened median time to COVID-19 viral negativity (mild to moderate cohorts) in a small, randomized trial (n=84) done by the University of Hong Kong (China).

They include: Lopinavir-Ritonavir, commonly used to treat HIV Dexamethasone, a type of steroid use in a range of conditions to reduce inflammation Hydroxychloroquine, a treatment for malaria The trial is being conducted in over 130 NHS hospitals across the UK.

The four treatments to be studied are remdesivir, lopinavir and ritonavir in combination, the latter being administered with or without interferon beta and hydroxychloroquine, French public health research body Inserm said in a statement on Sunday.

SOLIDARITY is examining four promising drug regimens: 1) Remdesivir—an experimental antiviral medication; 2) Chloroquine and hydroxychloroquine—malaria medications; 3) Lopinavir and ritonavir—two HIV drugs that may be useful in combination; and 4) Lopinavir, ritonavir plus interferon-beta, a medication